Cost-effectiveness analysis of radical cure strategies for Plasmodium vivax
Tafenoquine alongside quantitative screening for glucose-6-phosphate dehydrogenase (G6PD)
deficiency provides new opportunities for the treatment and control of Plasmodium vivax malaria. This tool
is designed to help malaria control programs and decision makers start to think about the cost-effectiveness
of different options for the treatment of vivax malaria, including:
Strategy 1 is unsupervised primaquine without G6PD screening.
Strategy 2 is unsupervised primaquine after screening with a qualitative G6PD test.
Strategy 3 is unsupervised primaquine after screening with a quantitative G6PD test.
Strategy 4 is tafenoquine after screening with a quantitative G6PD test.
The initial model parameters are set for adult patients (aged 16+) in Ethiopia, drawing largely on data from the IMPROV trial. Further details on the input values and how to update these are found in the dictionary. Users can switch between using low or high dose primaquine for Strategies 1-3, but the efficacy of tafenoquine remains equal to low-dose primaquine. Only the costs to the healthcare providers are included.
While this is a helpful tool to see how inputs impact the results, we recommend doing a full cost-effectiveness analysis with sensitivity analyses before changing policy.